2016 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle
11/29/16Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
Number of Patients with Complete Clearance of Genital Warts Provides Clinical Evidence of Nitric Oxide Anti-Viral Activity Against HPVCompany Plans End-of-Phase 2 Meeting for First Half of 2017 MORRISVILLE, N.C. , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced top-line results from the Company's Phase 2 clinical trial with SB206 for the treatment of  genital warts caused by human papillomavirus, or HPV. The highest dose test... 
11/23/16Novan to Present at Piper Jaffray 28th Annual Healthcare Conference
MORRISVILLE, N.C., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Nathan Stasko, PhD, President and Chief Executive Officer of Novan, is scheduled to participate in a fireside chat at the Piper Jaffray 28th Annual Healthcare Conference, Tuesday, Nov. 29, 2016, 4:30 p.m. EST, in New York. The presentation will be webcast live and can be accessed through the Investor Relations section of the Company's website at www.Novan.com. An ar... 
11/16/16Novan Announces Preclinical Data Demonstrating Immunomodulatory Effect In Vivo
Topical Application of SB414 Inhibited IL-17 in Psoriasis Mouse Model Effect Relates to Multiple Inflammatory Skin Diseases MORRISVILLE, N.C. , Nov. 16, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced preclinical data showing that the Company's nitric oxide-releasing product candidate SB414 significantly (p<0.05) reduced composite psoriasis scores, which consist of erythema and plaque scores, and pro-inflammatory cytokines, including in... 
11/14/16Novan Reports Third Quarter 2016 Financial Results
MORRISVILLE, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced the Company’s financial results for the third quarter of 2016. Total operating expenses for the three months ended Sept. 30, 2016, were approximately $17.5 million, which includes research and development, or R&D, expenses totaling approximately $15.0 million and general and administrative, or G&A, expenses totaling approximately $2.5 million. Total operating expens... 
10/18/16Novan to Present Data from SB204 Phase 2b Trial at Fall Clinical Dermatology Conference
DURHAM, N.C., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that results from the Company’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris, or acne, will be presented at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. This presentation will include the results of efficacy assessments and additional data re... 
09/28/16Novan Announces Both SB204 Phase 3 Pivotal Trials Fully Enrolled
More than 2,600 Subjects Enrolled Ahead of Schedule Top-Line Results Expected in First Quarter of 2017 DURHAM, N.C., Sept. 28, 2016 /PRNewswire/ -- Novan, Inc. (the "Company" or "Novan") (NASDAQ: NOVN) today announced that the last patient has been randomized in the Company's two, identically designed Phase 3 pivotal clinical trials to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 Gel in the treatment of acne vulgaris, or acne. Novan announced... 
09/26/16Novan Announces Closing of Initial Public Offering
Underwriters Exercised in Full Option to Purchase Additional Shares DURHAM, N.C., Sept. 26, 2016 /PRNewswire/ -- Novan, Inc. (the "Company" or "Novan") (NASDAQ: NOVN) today announced the closing of the Company's initial public offering of 4,715,000 shares of common stock at a price to the public of $11.00 per share, which includes the exercise in full by the underwriters of their option to purchase from the Company an additional 615,000 shares of common stock at the initial public offe... 
09/20/16Novan Announces Pricing of Initial Public Offering of Common Stock
DURHAM, N.C., Sept. 20, 2016 /PRNewswire/ -- Novan, Inc. (the "Company" or "Novan") today announced the pricing of the Company's initial public offering of 4,100,000 shares of common stock at a price to the public of $11.00 per share. The common stock of Novan has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "NOVN" on Sept. 21, 2016. All of the common stock is being offered by Novan. The Company has also granted the underwriters a... 
07/21/16Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Top-Line Results Expected in First Half of 2017       DURHAM, N.C. (July 21, 2016) – Novan, Inc. today announced that the first patient has been dosed in the Company's Phase 2 clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum ("T. rubrum"). Novan is developing SB208 as a broad-spectrum anti-fungal gel for the treatment of infections of the skin and nails, inc... 
05/10/16Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206
Preclinical Data Demonstrating Novel Mechanism of Action for the Treatment of HPV-Associated Warts to be Presented During Society for Investigative Dermatology Annual Meeting DURHAM, N.C. (May 10, 2016) – Novan, Inc. today announced that Kimberly McHale, Ph.D., Novan Senior Scientist, Research & Nonclinical Development, will present data demonstrating a novel mechanism of action for the Company's anti-viral product candidate, SB206, Saturday, May 14, at the 75th Annual Meeting of the Soc... 
03/01/16Novan's Phase 2b Results with SB204 to be Presented at AAD
Abstract Accepted for Presentation by Dr. Lawrence Eichenfield During 2016 Late-breaking Research in Dermatology Forum DURHAM, N.C. (March 1, 2016) – Novan, Inc. today announced that data from a Phase 2 clinical trial to evaluate the efficacy and safety of the Company’s topical nitric oxide product candidate SB204 Gel for the treatment of acne vulgaris will be presented at the 74th Annual Meeting of the American Academy of Dermatology (“AAD”) in Washington, D.C.Lawrence Eichenfield, MD, is sched... 
02/23/16Novan Announces First Patient Dosed in Phase 3 Program for SB204
Top-Line Results Expected in First Half of 2017  DURHAM, N.C. (February 23, 2016) – Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris (“acne”). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017.“Dosing the first patient in our Phase... 
02/08/16Novan Announces Robert A. Ingram as Chairman
Board Changes Follow Closing of $32.8 Million in Private Financing in December 2015  DURHAM, N.C. (February 8, 2016) – Novan, Inc. today announced that Director Robert A. Ingram has been named Chairman of the Board of Directors of Novan. In addition, Robert Keegan has been appointed to the Board of Directors.The Company also announced that it received a total of $32.8 million of net proceeds in a private Mezzanine B financing in December 2015 from its private investor network originating th...